A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus on obtaining safety data in adult participants. Cohort 1 and Cohort 2 (optional for dose exploration) will include participants ≥ 18 years of age. Cohort 3 will include participants ≥ 7 to \< 18 years of age and will be initiated following data and safety monitoring board (DSMB) recommendations. Participants will be monitored for 5 years post-administration of SGT-501 including the active treatment period (1 year) and long-term follow-up (LTFU) (4 years) period.

NCT Number	NCT07148089
Lead Sponsor	Solid Biosciences Inc.
Conditions	Catecholaminergic Polymorphic Ventricular Tachycardia
Enrollment	18 participants
Start Date	2026-02-23
Primary Completion	2027-06 (estimated)
Study Completion	2031-05 (estimated)
Updated on ClinicalTrials.gov	2026-08-10